Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy - Rose, A AN; Armstrong, S M; Hogg, D (J Immunother Cancer, 2021)